Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma

Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma

Abstract Lenalidomide (LND) is an anti-cancer drug and an effective derivative of thalidomide used for multiple myeloma therapy. Because of its poor solubility in water, LND is known to cause low oral bioavailability (below 33%), and as a direct consequence of this, the dosing frequency is extended...

Full description

Bibliographic Details
Main Authors: Veera Venkata Satyanarayana Reddy Karri, Nagasamy Venkatesh Dhandapani, Sai Sandeep Mannemala, Kollipara Radhakrishna, Shashank Mulukutla, Dedeepya Sudunagunta
Format: Article
Language:English
Published: Universidade de São Paulo 2017-06-01
Series:Brazilian Journal of Pharmaceutical Sciences
Subjects:
Multiple myeloma/treatment
Lenalidomide/uses
PLGA/sustained release
Polymeric nanoparticles/development
Solubility
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502017000200602&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502017000200602&lng=en&tlng=en

Similar Items